COZADD BRUCE C 4

What Happened

• Bruce C. Cozadd, a director of Jazz Pharmaceuticals (JAZZ), sold 6,000 shares on July 1, 2026. The reported sale price was $240.47 per share for a total proceeds of $1,442,820. This was a sale (not a purchase), which is often routine for insiders and does not by itself indicate company performance.

Key Details

• Transaction date and price: July 1, 2026 — 6,000 shares at $240.47 each.
• Total value: $1,442,820.
• Transaction type: Reported as an open-market or private sale (code S).
• Shares owned after the transaction: Not specified in the provided filing.
• Footnote: The sale was made under a pre-established Rule 10b5-1 trading plan adopted by Mr. Cozadd on November 26, 2025; the filing states the sale occurred automatically and was non‑discretionary.
• Filing timeliness: Report filed July 6, 2026. Considering the July 4 weekend/holiday timing, this appears to be within the Form 4 two-business-day filing window.

Context

• Sales by directors can be for many personal reasons (diversification, tax planning, pre-set plans). Because this transaction was executed under a 10b5-1 plan and was a sale, it should be viewed as a routine insider disposition rather than a clear signal about Jazz’s near-term prospects.